Rupam Manna/LinkedIn
Aug 17, 2026, 00:33
Rupam Manna: CELMoDs – Next-Generation Molecular-Glue Protein Degraders
Rupam Manna, Postdoctoral Student – DrNB Medical Oncology at National Board of Examinations, shared a post on X:
“CELMoDs: next-generation molecular-glue protein degraders.
By binding cereblon, CELMoDs redirect the CRL4–CRBN E3 ubiquitin ligase toward IKZF1 and IKZF3.
Their proteasomal degradation suppresses IRF4–MYC signalling, promotes myeloma-cell apoptosis and activates T and NK cells.
Key agents:
- Iberdomide – first FDA-approved CELMoD
- Mezigdomide – investigational in multiple myeloma
- Golcadomide – investigational in lymphoma
Remember the major class toxicities: neutropenia, infections, anaemia and thrombocytopenia.”

Stay updated with Hemostasis Today.
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C
-
Nov 16, 2026, 12:52Frank Nocken: Alzheimer’s Research Expands Beyond Amyloid-Based Treatments